Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Merck is closing in on a $10bn (€8.5bn) deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported.

A representative from clesrovimab's sponsor Merck said that each death was studied by investigators and none were deemed related to either RSV or the intervention.

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans receive seasonal influenza shots that are free from the mercury-based ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established science and practices, and limits on vaccines that have been studied for ...